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Historically, atypical pneumonia was a term used to describe an unusual presentation of
pneumonia. Currently, it is used to describe the multitude of symptoms juxtaposing
the classic symptoms found in cases of pneumococcal pneumonia. Specifically,
atypical pneumonia is a syndrome resulting from a relatively common group of
pathogens including Chlamydophila sp., and Mycoplasma pneumoniae. The incidence
of M. pneumoniae pneumonia in adults is less than the burden experienced by children.
Transmission rates among families indicate children may act as a reservoir and maintain
contagiousness over a long period of time ranging from months to years. In adults,
M. pneumoniae typically produces a mild, “walking” pneumonia and is considered
to be one of the causes of persistent cough in patients. M. pneumoniae has also
been shown to trigger the exacerbation of other lung diseases. It has been repeatedly
detected in patients with bronchitis, asthma, chronic obstructive pulmonary disorder,
and cystic fibrosis. Recent advances in technology allow for the rapid diagnosis of
M. pneumoniae through the use of polymerase chain reaction or rapid antigen tests.
With this, more effort has been afforded to identify the causative etiologic agent in
all cases of pneumonia. However, previous practices, including the overprescribing
of macrolide treatment in China and Japan, have created increased incidence of
macrolide-resistant M. pneumoniae. Reports from these countries indicate that >85%
of M. pneumoniae pneumonia pediatric cases are macrolide-resistant. Despite its
extensively studied past, the smallest bacterial species still inspires some of the largest
questions. The developments in microbiology, diagnostic features and techniques,
epidemiology, treatment and vaccines, and upper respiratory conditions associated with
M. pneumoniae in adult populations are included within this review.
Keywords: Mycoplasma pneumoniae, pneumonia, atypical pneumonia, community-acquired pneumonia, walking
pneumonia, CARDS toxin
INTRODUCTION
Mycoplasma pneumoniae, was first discovered in Eaton et al. (1944). It was originally known as
the Eaton agent. The tiny pathogenic agent could pass through a sterile filter, but could not be
grown on standard bacteriologic media. Thus, during that time, it was originally thought to be a
virus. Volunteer and field studies during the 1950s and early 1960s provided evidence verifying
the Eaton agent was a cause of lower respiratory tract infections in humans (Chanock et al., 1960,
1961; Mufson et al., 1961). Chanock et al. (1962) was able to culture the Eaton agent on a cell-free
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medium and proposed both the taxonomic designation as well as
the name of the organism as we know it today.
Currently, as one of the most studied mycoplasmas, a large
collective knowledge on M. pneumoniae has accumulated. Recent
discoveries in microbiology and improvements in diagnostic
techniques and treatments have led to dramatic advances. At the
same time knowledge regarding M. pneumoniae epidemiology,
associated upper respiratory conditions, and vaccine candidates
has also expanded. These topics and how they affect adult
populations will be briefly covered in this review.
MICROBIOLOGY
With a small cell size and volume, just 1–2 µm long and 0.1–
0.2 µm wide, mycoplasmas cannot individually be detected by
light microscopy (Waites and Talkington, 2004) and colonies
rarely exceed 100 µm in diameter. Sequenced in Himmelreich
et al. (1996), the genome of M. pneumoniae was shown to consist
of only 816,394 bp and 687 genes. Because of this small genome,
the organism is limited in its capabilities and unable to synthesize
rigid peptidoglycan cell walls. Alternatively, sterols provide the
structural support in the triple-layer cell membrane. As a result,
these organisms are insensitive to β-lactam antimicrobial agents,
pleomorphic, and are unaffected by the gram staining method.
Mycoplasma pneumoniae reproduces via binary fission with
well-organized chromosome segregation. Preceding binary cell
fission, the attachment organelle, a specialized cellular structure
that is responsible for cytadherence of this bacterium, duplicates
(Krause and Balish, 2004; Balish, 2006; Balish and Krause, 2006).
The resulting daughter organelle will migrate to the opposite pole
of the cell before the completion of chromosomal separation.
After duplication of chromosomal and cellular material, the now
polar opposite attachment organelles will simultaneously bind
to a surface and initiate gliding motility, pulling away from the
central point; thus, creating daughter cells (Bredt, 1968; Miyata
and Ogaki, 2006).
The attachment organelle is also crucial for host cellular
interactions. Cytoskeletal proteins found within and around
the attachment organelle facilitate adherence and motility. Of
note, P1 and supporting proteins P30, P90, and P40 promote
adhesion and binding to host cells via sialic acid receptors
(Krivan et al., 1989; Roberts et al., 1989; Razin and Jacobs,
1992; Seto and Miyata, 2003; Waldo and Krause, 2006; Chaudhry
et al., 2007), while P1, P30, P41, and P200 promote and
regulate gliding motility (Kenri et al., 2004; Krause and Balish,
2004; Seto et al., 2005; Hasselbring and Krause, 2007; Jordan
et al., 2007). Many authors allude to a cellular construction
based on electron micrograph observations of cryosections
(Hegermann et al., 2002; Henderson and Jensen, 2006; Seybert
et al., 2006; Nakane et al., 2015). Integration and interpretation
of these studies propose that the attachment organelle is
connected to a rod consisting of two paired plates (rods),
one thick and one thin, which is attached, at the proximal
end, to a wheel-like protein complex (bowl-complex), the
wheel (bowl) further connects to other cytoskeleton filaments
in the peripheral cell. A schematic, assembled from literature
interpretation, is depicted in Figure 1 (Meng and Pfister, 1980;
Razin et al., 1998; Trachtenberg, 1998; Krause and Balish, 2001,
2004; Hegermann et al., 2002; Henderson and Jensen, 2006;
Miyata and Ogaki, 2006; Seybert et al., 2006; Nakane et al.,
2015). However, the exact mechanism by which the attachment
organelle and associated structures and proteins initiate motility
is still relatively unknown, although numerous authors support
inchworm-like movement (Henderson and Jensen, 2006; Hatchel
and Balish, 2008; Nakane et al., 2015).
Mycoplasma pneumoniae has not been found freely
living in nature. It is predominantly considered a mucosal
pathogen existing parasitically on the epithelial surface of its
host. Interactions between M. pneumoniae and host tissue,
continuously show the attachment organelle bound to the
host cell surface (Wilson and Collier, 1976; Razin and Jacobs,
1992; Rottem, 2003). However, reports of internalization by
lung epithelial cells also exist (Yavlovich et al., 2004). It is
assumed cytadherence protects mycoplasma from clearance
via the mucociliary apparatus and this attachment is ultimately
considered the initiating event of disease.
PATHOGENESIS
Once bound to host tissue, pathogenic processes begin to occur.
Hydrogen peroxide and superoxide, produced by M. pneumoniae
through the metabolism of glycerol, have been shown to cause
injury to epithelial cells and their associated cilia (Somerson
et al., 1965; Low, 1971; Tryon and Baseman, 1987; Minion and
Jarvill-Taylor, 1994). The effects of hydrogen peroxide on host
cells such as erythrocytes include denaturation of hemoglobin,
FIGURE 1 | A longitudinal schematic depicting the cellular architecture
of Mycoplasma pneumoniae. It contains known structural features
including cell shape, lack of flagella, a terminal organelle including the “rod”
composed of two segmented plates, one thick and one thin, and a wheel
(bowl) complex with fibrils extending throughout the cytoplasm. The outer cell
membrane is integrated with membrane proteins while the inner lining
encloses the cytoplasm. Image is not to scale.
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peroxidation of lipids, and eventual cell lysis. The same oxidative
stress in the respiratory epithelium can result in both structural
and functional deterioration of cilia (Waites and Talkington,
2004).
Recently discovered, the community-acquired respiratory
distress syndrome (CARDS) toxin has also been shown to
facilitate localized disruption and cytotoxicity (Kannan et al.,
2005, 2010; Kannan and Baseman, 2006; Johnson et al., 2011;
Becker et al., 2015). Cells exposed to this 68-kDa proteinaceous
toxin, with homologies to the pertussis toxin, exhibited distinct
vacuolization and cell rounding (Kannan and Baseman, 2006).
Other cellular effects of CARDS could include the loss of cilia,
reduced oxygen consumption, glucose utilization, and amino
acid uptake, as well as detachment and ultimate shedding of
the infected cells, documented elsewhere (Clyde, 1971, 1983;
Collier, 1983; Johnson et al., 2011). The dry, hacking cough
commonly associated with early infection, is most likely the
clinical manifestation of the aforementioned cellular damages
endured by the upper respiratory tract (Waites and Talkington,
2004).
The CARDS toxin has also been shown to activate its own
pathogenic response in animal models. A direct relationship
between the number of M. pneumoniae organisms, amounts
of the CARDS toxin, and severity of lung histopathology was
observed in murine models (Techasaensiri et al., 2010; Kannan
et al., 2011). Moreover, mice and baboons, which received
recombinant CARDS toxin alone, elicited cellular inflammation
similar to M. pneumoniae infection. This suggests the CARDS
toxin, plays a major role in pathogenesis (Hardy et al., 2009).
Further, research has shown the CARDS toxin can localize
with the NOD-like receptor containing pyrin domain 3 (NLRP3)
inflammasome and catalyze the ADP-ribosylation of NLRP3
(Bose et al., 2014). As a result, the CARDS toxin is the
first example of a toxin exhibiting both ADP-ribosylating and
vacuolating properties (Krueger and Barbieri, 1995; Kannan and
Baseman, 2006). In Figure 2, we propose a potential cell signaling
model based on information collected from previously published
reports (Fan et al., 2003; Yang et al., 2004; Chu et al., 2005; Xiang
and Fan, 2010; Johnson et al., 2011; Kannan et al., 2011; Franchi
and Nunez, 2012; Franchi et al., 2012; Bose et al., 2014; Saraya
et al., 2014; Shimizu et al., 2014; Vanaja et al., 2015).
Interaction between respiratory epithelial cells and surface
lipoproteins of M. pneumoniae is likely to induce the host
immune system via Toll-like receptor (TLR)-2 (Chu et al.,
2005; Kraft et al., 2008) or TLR-4 (Shimizu et al., 2014)
stimulating the synthesis of intracellular adhesion molecule
(ICAM) receptors. Stimulation and crosstalk of the TLRs can
trigger and amplify the production of chemokines promoting
lymphocyte and neutrophil trafficking and inflammation in the
lung (Fan et al., 2003; Yang et al., 2004; Saraya et al., 2011). In
addition to respiratory epithelial cells, M. pneumoniae has been
shown to directly activate and induce the production of cytokines
from unsorted peripheral blood leukocytes (Kita et al., 1992),
lymphocytes (Simecka et al., 1993; Medina et al., 2012), and
monocytes and macrophages (Yang et al., 2003; Broaders et al.,
2006). Opsonization may also occur but the evidence is minimal
since re-infection is common.
Macrophages, including alveolar macrophages likely play a
central role as an innate immune defense mechanism through
phagocytosis. Alveolar macrophages, in particular, can also
secrete pro-inflammatory cytokines, such as RANTES, which
is a known chemo-attractant for neutrophils and basophils
(Bischoff et al., 1993; Saraya et al., 2011; Tani et al., 2011).
According to some reports, the most distinguishing pathological
feature resulting from this organism in human pneumonia
is an increase of plasma cell-rich lymphocytic infiltration in
the peri-bronchovascular areas (PBVAs), with accumulation of
macrophages, neutrophils, and lymphocytes in alveolar spaces
(Coultas et al., 1986; Hayashi et al., 1986; Rollins et al., 1986;
Saraya et al., 2014).
The underlying cell-mediated immunity of the host also
plays an important role in the progression and development
of M. pneumoniae related diseases. Furthermore, cell-mediated
immunity level or predominant response is potentially correlated
to the variable pulmonary patterns seen in chest images (Tanaka
et al., 1996; Saraya et al., 2011, 2014). Multiple studies have
acknowledged the importance of IL-12, interferon-γ, and Th1
type T-cell responses during the course of M. pneumoniae
infections (Fonseca-Aten et al., 2005; Tagliabue et al., 2008;
Hardy et al., 2009; Techasaensiri et al., 2010). However, a
recombinant CARDS toxin has resulted in potent allergic-type
pulmonary inflammation characterized by T-cell dependence,
airway hyperreactivity, and production of Th2 type cytokines
(Medina et al., 2012). In sensitized mice, M. pneumoniae can
lead to Th2 type T-cell allergic inflammation (Chu et al.,
2003, 2005). While, other previous animal studies have shown
the histopathological score of M. pneumoniae pneumonia is
significantly higher in BALB/c mice (Th2 predominant) than in
C57BL/6 mice (Th1 predominant; Fonseca-Aten et al., 2005). The
collective interpretation of all these findings suggest an attractive
link to the differences observed in human host cell-mediated
immunity response against the organism and the resulting
variable pathogenic patterns seen in chest images and serological
responses (Kraft et al., 1998; Nisar et al., 2007; Atkinson et al.,
2009; Saraya et al., 2011).
EPIDEMIOLOGY
Mycoplasma pneumoniae is able to infect both the upper and
lower respiratory tracts and it can create both endemic and
epidemic situations among children and adults worldwide.
From 2001 to 2006, M. pneumoniae was the most common
atypical pathogen identified in 39 hospitals across 11 countries
(Arnold et al., 2007). However, most available data regarding
M. pneumoniae infections comes from studies performed in
Japan, Europe, and the United States. Within Europe, M.
pneumoniae is frequently included in regular surveillance, but
studies from arctic and tropical zones point to the many diverse
populations with infections due to this organism (Suhs and
Feldman, 1966; Golubjatnikov et al., 1975; Joosting et al., 1976;
Campos et al., 1993).
Mycoplasma pneumoniae has a diminutive size, which allows
it to spread from person to person through droplet infection
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FIGURE 2 | Possible schematic for pathogenesis of human M. pneumoniae. CARDS, Community Acquired Respiratory Distress Syndrome; ATP, adenosine
tri-phosphate; K, potassium; ICAM, intracellular adhesion molecule; NADPH, nicotinamide adenine dinucleotide phosphate; ROS, reactive oxygen species; TLR, toll
like receptor.
during close contact. Following a coughing event, contaminated
droplets disperse through the air. The eventual cytadherence by
the bacteria in an alternate host describes successful transmission.
Some patients may remain infectious for prolonged periods
despite the disappearance of many symptoms, other than cough
(Hallander et al., 1999; Wadowsky et al., 2002; Ishida et al., 2010;
Wang et al., 2011).
Immunity is not long lasting; the bacteria and its associated
disease can relapse in patients even after adherence to an effective
antibiotic regimen (Watson and Storch, 2008). The genomic
variation of the P1 adhesin may contribute to this complex
and recurring epidemiology. There are two main subtypes of
M. pneumoniae frequently isolated from clinical specimens (Su
et al., 1990), though other variants have been reported (Dorigo-
Zetsma et al., 2000; Dumke et al., 2010b; Pereyre et al., 2012).
Japan has reported the cycling of prevalent subtypes. Between
1995 and 2001, subtype 2 was accountable for the majority
of infections, but between 2002 and 2005, subtype 1 became
more prevalent (Kenri et al., 2008). It is not yet understood
if recurrence within one individual is caused by reactivated
infection or exposure to different genetic subtypes.
Interestingly, epidemic and endemic settings also report
a polyclonal spread of the bacteria (Chalker et al., 2011;
Pereyre et al., 2012, 2013), with multiple types or strains
propagating within the human population simultaneously. This
observation indicates point source infection is not the probable
cause of countrywide epidemics; rather, a more likely cause
is some environmental factor. Rates of M. pneumoniae vary
annually, yet cyclic epidemic patterns have been observed
every three to five years in long-term studies and geographic
surveillance (Lind et al., 1997; Nir-Paz et al., 2012). It has
been suggested most epidemics occur in either late summer
or autumn within North America (Alexander et al., 1966;
Feikin et al., 1999). However, other geographic regions report
maintained epidemics through all seasons (Foy et al., 1979;
Blystad et al., 2012; Nir-Paz et al., 2012; Polkowska et al.,
2012; Uldum et al., 2012). A recent study from Fukuoka,
Japan has reported climactic events related to the El Niño
Southern Oscillation and Indian Ocean Dipole were significantly
associated with monthly incidence of M. pneumoniae in both
2005–2007 and 2010–2011 (Onozuka and Chaves, 2014). These
weather events may be responsible for both the cyclic 3–5 years
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resurgence pattern as well as the differing seasonality across
continents.
In adults, M. pneumoniae is potentially responsible for
more than 35% of hospitalized community-acquired pneumonia
(CAP) cases (Marston et al., 1997; Dey et al., 2000; Cunha
and Pherez, 2009). However, a recent report from the Centers
for Disease Control and Prevention, estimated only 2% of
detectable pathogens in hospitalized CAP patients were due to
M. pneumoniae (Jain et al., 2015). Moreover, a report from
the Atypical Pathogens Reference Laboratory Database attributes
12% (range 11–15%) of global CAP incidence to M. pneumoniae
(Arnold et al., 2007). This last estimate does take into account the
fluctuation of both seasonal and outbreak years, covering almost
five winter seasons in its data analysis. However, patients with
CAP typically have mild symptoms and are treated as outpatients,
if at all. Therefore, the number of M. pneumoniae cases reported
may be an underestimation of actual burden.
Prevalence, documented in other studies, can have a wide
range Marston et al. (1997), reported 5.4% of CAP in hospitalized
adults in the United States was due to M. pneumoniae by
serology. Also using serology in Porath et al. (1997), from Israel,
reported 29.2% of hospitalized CAP adults were infected with
M. pneumoniae. Wattanathum et al. (2003), Thailand reported
similarly high rates by serology, with 29.6% of outpatients
with symptoms due to M. pneumoniae. Whereas, von Baum
et al. (2009), polymerase chain reaction (PCR) and serological
analysis from Germany showed 6.8% of CAP cases were due
to M. pneumoniae, of which 55% were treated as outpatients.
Prevalence reporting for most countries, however, is difficult due
to the non-availability of reliable, rapid diagnostic techniques and
an organized reporting system (Kashyap and Sarkar, 2010).
We calculated an estimated number of M. pneumoniae
cases per 100,000 people by linear interpolation based on
in country reports collected during our review process (Bii
et al., 2002; Chaoprasong et al., 2002; Accomando et al.,
2004; Nagalingam et al., 2004; Obeidat et al., 2005; Matute
et al., 2006; Petitjean Lecherbonnier et al., 2006; Shankar et al.,
2006; Somer et al., 2006; Kung, 2007; Huang et al., 2008;
Boettcher et al., 2010; Prodromidou et al., 2010; Touati et al.,
2010; Eick et al., 2011; Song et al., 2011; Wang et al., 2011;
Bajraktarevic et al., 2012; Blystad et al., 2012; Feikin et al., 2012;
Hoffmann et al., 2012; Lenglet et al., 2012; Polkowska et al., 2012;
Uldum et al., 2012; Wellinghausen et al., 2012; Chen et al., 2013,
2015; Hong et al., 2013; Kawai et al., 2013; Luchsinger et al., 2013;
Wu et al., 2013; Carrim et al., 2014; Grassi et al., 2014; Moore
et al., 2014; Neocleous et al., 2014; Zhao et al., 2014; Kogoj et al.,
2015; Liu et al., 2015). The resulting data is shown in Figure 3,
with elevated rates possibly found throughout China, Russia,
Mexico, and Brazil.
The majority of outbreaks have occurred within a community
or in closed or semi-closed settings such as military bases
or universities (Mogabgab, 1968; Edwards et al., 1976; Gray
et al., 1997, 1999; Feikin et al., 1999; Crum et al., 2005;
Walter et al., 2008; Centers for Disease Control and Prevention
[CDC], 2012, 2013; Waller et al., 2014), hospitals (Fischman
et al., 1978; Kashiwagi et al., 1985; Kleemola and Jokinen, 1992;
Hyde et al., 2001; Shangguan et al., 2014), and facilities for
FIGURE 3 | Interpolated M. pneumoniae incidence from 2000 to 2012.
These statistics were calculated using linear interpolation from reported
incidence found within the literature. Gray countries were incalculable. This
interpolation process did not take into account any genetic, cultural,
environmental, social, or other differences across the various countries and
regions. Thus, interpolations may have very limited relevance to the actual
incidence of M. pneumoniae in any region. Image created using R v.3.2.2 with
the package choroplethr.
the developmentally disabled or elderly (Marrie, 1993; Klausner
et al., 1998; Hastings et al., 2015). Although, these outbreaks can
disrupt and consume significant resources in the workforce, long-
term morbidity is uncommon (Waites and Talkington, 2004).
Controlling an outbreak often includes simple strategies such as,
cohorting infected patients and the correct use of antibiotics as
treatment.
CLINICAL MANIFESTATIONS
In the acute phase of infection, a dry cough develops which
may progress to a wet cough in 3–4 days. Coughing represents
progressing tracheobronchitis, the most common form of
infection. Chest auscultation may be unhelpful for diagnosis in
most situations, but scattered rhonchi and expiratory wheezes
may sometimes present (Norisue et al., 2008). If pneumonia
develops, atypical pneumonia is the predominant syndrome
observed in adult patients. The syndrome is portrayed by the
gradual onset of pharyngitis, sinus congestion, infrequent otitis
media, and eventually prolonged lower respiratory involvement
up to and including pneumonia with low-grade fever and
bibasilar pulmonary infiltrates. The incubation period prior to
symptom emergence may be short or as long as 3 weeks. In
severe pneumonia cases, dry rales and frank consolidation may
be observed, but this is fairly uncommon, and may be due to
co-infection with Streptococcus pneumoniae or Chlamydophila
pneumoniae (Nambu et al., 2006; Norisue et al., 2008).
There may be mild leukocytosis, but the total white blood cell
count does not often exceed 15,000/µL. Expectorated sputum
is not viscous. If sputum is sufficient, gram staining shows
nothing discernable due to the small size of M. pneumoniae and
its lack of cell wall. Severe cough and chest images depicting
bronchopneumonia are common, as inflammation occurs in
response to ciliated cell damage. Respiratory symptoms in severe
pneumonia cases may necessitate admission to the hospital due
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to decreased blood oxygen and increasingly labored breathing.
The most common radiological and high resolution computed
tomography (CT) images of M. pneumoniae pneumonia include
air-space opacification, bronchovascular thickening, atelectasis,
nodular infiltration, and linear opacities outward from the
hilum, but are indistinguishable from other bacterial or viral
pneumonia patterns (Reittner et al., 2000; Miyashita et al., 2009).
Putman et al. (1975) proposed three possible reasons for alternate
chest images: the existence of an underlying or co-existing
pulmonary disease, previous exposure to M. pneumoniae, or the
varied immune response and host susceptibility. To date, many
researchers favor prior exposure (Saraya et al., 2011; Medina et al.,
2012) and host immune differences (Tanaka et al., 1996; Saraya
et al., 2014). Still, others report alternate host differences such
as age (Lee et al., 2006), health conditions (Lambert, 1968), or
environmental factors (Putman et al., 1975; Yang et al., 2004).
Severity of disease has also been shown to be strain- and toxin
concentration-dependent (Techasaensiri et al., 2010).
As mentioned previously, the cell-mediated immunity of
patients may have a strong impact on the course of disease
development following M. pneumoniae infection (Putman et al.,
1975; Tanaka et al., 1996; Yang et al., 2002; Saraya et al.,
2011, 2014). Some studies report detection of M. pneumoniae
in seemingly healthy individuals. One such study reports peak
incidence of 13.5% of 758 healthy volunteers (Gnarpe et al., 1992),
while another study detected positive throat cultures 4 months
after illness (Foy et al., 1966). It is possible these asymptomatic
or mild infections still allow for shedding of the pathogen. These
patients may act as a reservoir from which further spreading
can occur. Similar to other respiratory infections, the duration
of signs and symptoms will be shorter if antibiotics are initiated
early in the course of infection.
Other Respiratory Manifestations
It has been suggested M. pneumoniae infection contributes
to the development of chronic respiratory diseases, including
persistent cough and asthma. While medical care for a persistent
cough is frequently sought out, this symptom is commonly
associated with M. pneumoniae in children (Hallander et al.,
1999; Wang et al., 2011) and older adults (Miyashita et al., 2008;
Takahashi et al., 2009). The organism may be found frequently
in school-aged children with persistent cough particularly during
active epidemics of M. pneumoniae (Wang et al., 2011) or
concurrently with Bordetella pertussis (Hallander et al., 1999).
Similar outbreaks of persistent cough are likely to occur in other
ideal settings, such as dormitories, among military recruits, and
in hospitals or nursing homes. In Japan, M. pneumoniae was
confirmed by serology in 5.5% of adult patients with persistent
cough (Ishida et al., 2010). Despite this evidence, Wadowsky et al.
(2002), concludes M. pneumoniae is infrequently the active agent
of cough illnesses longer than 5 days in adolescents and adults.
However, cough may persist after acute infection in adults due
to the continued presence of mycoplasma cell products or the
CARDS toxin (Kannan et al., 2011).
Mycoplasma pneumoniae has for a long time been implicated
in the exacerbation of asthma (Biscardi et al., 2004; Nisar et al.,
2007; Hong, 2012; Wood et al., 2013). Moreover, some studies
have isolated the bacteria in higher prevalence among asthmatics
(Kraft et al., 1998; Smith-Norowitz et al., 2013). Sutherland
et al. (2004), evaluated a questionnaire given to patients with a
history of CAP after an episode of pneumonia. There, patients
with a history of atypical pneumonia were more likely to be
asthmatics. Other studies go on to document M. pneumoniae
infection preceding an initial asthmatic event (Mok et al.,
1979; Yano et al., 1994; Biscardi et al., 2004). It is possible
mycoplasma infection leads to the destruction of respiratory cells
and facilitates mucosal penetration by other antigens. Thereby,
allowing the patient to become atopic to M. pneumoniae and
other allergens (Nisar et al., 2007). However, at this time, none
of these studies have distinguished increased susceptibility or
exposure to M. pneumoniae from genetic predisposition for
asthma (Mok et al., 1979).
Although, the M. pneumoniae connection with asthma is well-
established, the mechanism behind development of the disease
is still relatively unknown. One clue to pathogenesis in this
regard may be immunoglobin (Ig) E responses. Some studies
have reported control patients, may be capable of mounting
a higher antibody response than those with asthma (Kraft
et al., 2002; Atkinson et al., 2009; Wood et al., 2013). The
role of T lymphocytes in the pathogenesis of asthma has been
well-documented. The release of type 2 cytokines, including
interleukin (IL)-4 and 5, is also increased in the serum of patients
with M. pneumoniae (Esposito et al., 2002; Jeong et al., 2012).
These cytokines in turn promote IgE production, which also
plays a part in asthma. Also, antigenic mycoplasmas may initiate
an antibody response resulting in IgE attaching to mast cells
interacting with M. pneumoniae, which ultimately stimulates
histamine release (Gil et al., 1993). However, additional studies
are needed to fully understand the role of M. pneumoniae plays
in the initial onset and exacerbation of asthma.
Extrapulmonary Manifestations
Extrapulmonary manifestations, although less common, have
also been described. Patients with compromised immunity,
including humoral immunodeficiences may be at higher risk for
developing these complications. Extrapulmonary complications
may occur in no more than 10% of patients with M. pneumoniae.
Central nervous system (CNS) complications comprise the
bulk of commonly seen extrapulmonary manifestations (Guleria
et al., 2005). Such complications include, encephalitis, meningitis,
optic neuritis, and Guillain–Barré syndrome among others.
The mechanism of action behind these ominous manifestations
remains unknown. In most patients, respiratory illness precedes,
2–14 days before, CNS findings (Tsiodras et al., 2005). CNS
complications may result from direct invasion of M. pneumoniae
in the brain (Tsiodras et al., 2005) or through extreme
immune-mediated damages (Lee et al., 2013). Immune-mediated
responses could be the result of cross-reacting antibodies and
antigens shared by M. pneumoniae and the brain, depression
of T-lymphocyte function, immune complex deposition, or
intravascular clotting (Guleria et al., 2005; Tsiodras et al., 2005;
Johnson, 2006).
Dermatological conditions such as erythematous
maculopapular, vesicular rashes and Stevens-Johnson syndrome,
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are also somewhat common as extrapulmonary manifestations
(Walicka et al., 2008; Kashyap and Sarkar, 2010; Kunimi
et al., 2011; Shimizu et al., 2012). Whereas, hematological,
gastrointestinal, musculoskeletal, renal and other inflammatory
manifestations have occurred in rare cases (Cameron et al.,
1992; Perez et al., 1997; Parisi and Filice, 2001; Perez and
Artola, 2001; Waites and Talkington, 2004; Johnson et al., 2007;
Atkinson et al., 2008; Maia et al., 2009; Kashyap and Sarkar,
2010; Bayram et al., 2011). Further, information regarding the
details of extrapulmonary diseases as a result of M. pneumoniae
can be found in numerous case reports. However, because
M. pneumoniae is quite common, there is the possibility some of
these instances are only coincidental.
DIAGNOSIS
As a common cause of illness for both children and adults,
M. pneumoniae should regularly be considered as a possible
etiology in any upper respiratory infection, especially in
immunocompromised patients or patients who have not
responded to β-lactam antibiotics. Recently, there are many new
techniques adapted to detecting the presence of M. pneumoniae
suitable for both research and diagnostic purposes. These
techniques were described in length by Daxboeck et al. (2003).
Here, we will include a brief review and updated techniques.
The Japanese Respiratory Society (JRS) developed a scoring
system to differentiate between typical and atypical pneumonia
(Ishida et al., 2007) using clinical findings. The differential
items include: (1) patient under 60 years of age; (2) no or
minor underlying diseases; (3) stubborn cough; (4) poor chest
auscultatory findings; (5) no sputum or etiologic agent identified
by gram staining; and (6) a peripheral white blood cell below
10,000/µL. In cases where a patient presents with four or
more of the six items, JRS guidelines recommend the use
of macrolides or tetracyclines because of a suspected atypical
pneumonia.
Many countries consider the most reliable diagnosis for acute
pneumonia infection would come from a combination of two
or more separate laboratory methods, such as serology and PCR
(Petitjean et al., 2002; Daxboeck et al., 2003; Martinez et al., 2008;
Nilsson et al., 2008; Chaudhry et al., 2013), or a clinical prediction
rule, such as the JRS scoring system, with a rapid laboratory test
(Ishida et al., 2007; Miyashita et al., 2011, 2015). The use of the
laboratory tests listed below along with clinical prediction rules
can more easily distinguish among acute, persistent infection and
asymptomatic patients.
Historically, the use of cold agglutinins and detection of
M. pneumoniae by culture methods were widespread diagnostic
techniques. Cold agglutinin testing was once considered a
valuable tool, but it is not a highly specific indicator of
M. pneumoniae, as autoantibodies in the blood can be elevated
from other diseases or syndromes (Jacobs, 1993; Beersma et al.,
2005). A decade ago, the complement fixation (CF) method that
detects the human body’s early responses to M. pneumoniae was
common around the world. A single 1:64 CF titer was considered
an indication of recent M. pneumoniae infection. However, the
CF test has a well-documented lack of sensitivity and specificity
(Ponka et al., 1981; Waites and Talkington, 2004).
Rapid Diagnostics
Currently, a more advanced test using a similar method to
CF is the microparticle agglutination assay (MAG), wherein
specific antibodies to M. pneumoniae create hemagglutination
and erythrocytes are replaced by latex particles to avoid non-
specific reactions (Barker et al., 1990). Additionally, in August
2013, two rapid antigen kits for the detection of M. pneumoniae
in nasopharyngeal samples became available in Japan (Miyashita
et al., 2015; Yamazaki et al., 2015). These rapid antigen kits detect
two different targets L7/L12 ribosomal protein or P1 adhesion
protein. Two studies have compared the ribosomal protein
rapid antigen kit to real-time PCR and the resulting theoretical
diagnostic sensitivities were approximately 60% (Miyashita et al.,
2015) and 74% (Yamazaki et al., 2015) in these samples. Hatano
et al. (2013), reported the use of this rapid P1 adhesion
protein detecting kit in 462 patients with a resulting sensitivity
and specificity of 90 and 89.5%, respectively. However, further
prospective studies are needed to evaluate the sensitivity of these
rapid tests more thoroughly.
Rapid diagnostic tests are most useful in the early stages
of CAP to assist decisions related to patient therapy. Despite
the development of these two tests, however, the majority of
M. pneumoniae cases continue to be diagnosed using serological
methods or through the detection of nucleic acids. A variety of
tests have been developed in this regard, each with their own
advantages and disadvantages. However, numerous confounding
variables inherent to the pathogenesis of M. pneumoniae
contribute to obscuring the diagnostic accuracy of laboratory
methods.
Serology
Serology remains as relevant now as it was in the past for the
diagnosis of M. pneumoniae. The ease of sample collection
coupled with further regard to conclusive evidence of
M. pneumoniae as the causative agent, maintain serology’s
presence within diagnostics. There are currently several
commercially available serological tests utilizing a variety of
methods to detect the presence of M. pneumoniae.
Enzyme immunoassays (EIAs) use whole-cell lysates,
containing glycolipid antigens, or protein extracts without
glycolipid antigens. IgG seroconversion in M. pneumoniae
infected patients is estimated to occur from 3 to 8 weeks
following infection. EIAs are more sensitive than both the CF
and MAG tests (Moule et al., 1987; Aubert et al., 1992; Nir-Paz
et al., 2006) for detecting acute infection. Most EIAs implement
a 96 well-microtiter plate. However, rapid membrane based
procedures are available for the detection of a single specimen
(Alexander et al., 1996; Matas et al., 1998).
For diagnosis during acute infection, a separate detection
of IgM or IgA is useful. IgM antibodies appear in the first
week of illness and reach their highest titers during the third
week (Jacobs, 1993). IgA antibodies are also produced in early
stages of the disease (Watkins-Riedel et al., 2001). Assays for
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IgM and IgA detection are primarily based on the enzyme-
linked immunosorbent assay (ELISA) principle. Rapid assays,
like those previously mentioned are also available and generally
use direct immunoflourescence, counter immunoelectrophoresis,
immunoblotting or antigen capture EIs (Kashyap and Sarkar,
2010). Talkington et al. (2004) and Beersma et al. (2005), more
thoroughly evaluated commercially available EIAs.
Despite its many strengths and versatility, serology lacks
sensitivity. Many ELISA tests have the possibility of false
positive results by cross-reactions with other mycoplasma species
(Morrison-Plummer et al., 1987). Additionally, antibodies to
M. pneumoniae may not appear until 2 weeks following initial
infection and onset of symptoms (Vikerfors et al., 1988).
Other studies report substantially longer times until positive
serology results (Nir-Paz et al., 2006; Nilsson et al., 2008; Zhang
et al., 2011). Further still, physicians must also consider the
status of a patient’s immune system. Particularly, in adults
the response to IgM may be non-specific or absent (Uldum
et al., 1992); while other underlying conditions may indicate an
immunocompromised patient. However, serology as a diagnostic
approach remains a convenient alternative for the detection of
M. pneumoniae in respiratory secretions.
Nucleic Acid Amplification
Polymerase chain reaction amplification from respiratory
secretions, such as nasopharyngeal, oropharyngeal, or sputum
samples can provide more sensitive detection. Many studies
have shown amplification methods can detect M. pneumoniae
even in seemingly healthy individuals (Leng et al., 1994; Tjhie
et al., 1997). PCR tests have been designed around the 16S
rDNA, P1 adhesion protein, and the ATPase operon genes of
M. pneumoniae. Sensitivity can be further increased by nested
PCR, which involves reamplification of a PCR product with a
different set of primers for the same target.
Quantitative real-time PCR (qRT-PCR) may also provide an
attractive alternative to serology and conventional PCR (Pitcher
et al., 2006). It is as sensitive as conventional PCR with the
additional possibility of quantitative capabilities, which may
indicate acute infections. The qRT-PCR method has also been
successful for rapidly and reliably distinguishing between the
two dominant M. pneumoniae types (Schwartz et al., 2009).
Furthermore, a qRT-PCR assay, designed to target the CARDS
toxin gene, proved to be the most sensitive assay to identify
positive specimens in an outbreak investigation and again in
other specimens (respiratory and cerebrospinal fluid) in sporadic
cases (Winchell et al., 2008). Currently, a commercially available
kit, implementing detection of the CARDS toxin gene does
not exist. A publication authored by Chaudhry et al. (2013)
indicates in-house qRT-PCR designed methods have a small but
significant increase in sensitivity over traditional PCR methods,
but primer design and standardization could be problematic for
less experienced laboratories.
The use of conventional PCR and qRT-PCR has standardized
the detection of M. pneumoniae along with other pneumonia and
atypical pneumonia inducing bacterial pathogens (Mustafa et al.,
2011). A recent study comparing four commercially available
multiplex PCR assays found performance across different
manufacturers remains relatively high and stable, with 93–100%
agreement for all comparisons (Anderson et al., 2013). Khanna
et al. (2005) developed a multiplex PCR assay for detection of five
pneumonia-causing bacteria; it is now available commercially.
The use of multiplex PCR or multiplex qRT-PCR technology
enables the detection of multiple pathogens simultaneously
with excellent sensitivity and specificity. Multiplex technology is
particularly useful for the diagnosis of CAP patients, in etiological
studies, or when broad-spectrum antibiotics fail to improve
patient conditions.
Developed in Japan, a new amplification technique called
loop-mediated isothermal amplification (LAMP) has also
been applied to rapid diagnosis of M. pneumoniae (Saito
et al., 2005; Yoshino et al., 2008; Kakuya et al., 2014). This
molecular amplification method occurs in a single tube
at constant temperature, eliminating the necessity of a
thermocycler. Endpoint analysis can be performed rapidly
by visual confirmation of turbidity and precipitates or can be
integrated into more advanced photometrics for more accurate
quantification. The sensitivity of the LAMP assay was 88.5%
compared to a validated qRT-PCR test on samples collected in
the United States, and no cross reactivity was observed against
17 other mycoplasma species, human DNA, nor other common
respiratory pathogens (Petrone et al., 2015). Unfortunately, due
to the limits inherent within primer design, multiplexing of
this assay is not possible. In the near future LAMP assays could
enable rapid, low cost detection of M. pneumoniae cases and
earlier recognition of outbreaks by medical providers (Petrone
et al., 2015), particularly in resource limited settings.
Culture Techniques
Although still seen as the “gold standard,” bacterial culture
for M. pneumoniae from oropharyngeal samples can be time
consuming due to the nutritive requirements. Specificity is
100%, when protocols are successful. Isolation of the pathogen
has advanced the knowledge surrounding extrapulmonary
manifestations, because successful isolation provides evidence
of direct invasion by living bacteria (Daxboeck et al., 2003).
Similar conclusions cannot be made from all positive PCR results,
because target DNA may still be detected in patients beyond
the death of the bacteria. However, the sensitivity of culture
for diagnosis can be low and dependent both on the skill of
the laboratory as well as the quality of the specimen. Thus,
M. pneumoniae is cultured with cell-free media formulations,
primarily for research purposes.
CHEMOTHERAPY AND VACCINES
These organisms lack a peptidoglycan cell wall, therefore therapy,
which interferes with DNA synthesis, i.e., quinolones, or protein
synthesis such as, macrolides and tetracyclines, are used more
frequently than beta-lactams and glycopeptides and generally
have a greater influence on disease (Niederman, 2001; Watkins
and Lemonovich, 2011). For young children, macrolides should
be considered first, due to potential severe side effects of
tetracyclines and quinolones (Suzuki et al., 2006).
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Macrolides are well-known for their antibiotic capabilities.
However, considerable data has also been gathered confirming
macrolides also possess anti-inflammatory properties, which can
also contribute to patient improvement (Gotfried, 2004; Tamaoki,
2004). Macrolides seem to modify or regulate the immune
system by inhibiting inflammatory cell chemotaxis, cytokine
synthesis, adhesion molecule expression, reactive oxygen species
production and intracellular signaling pathways (Kanoh and
Rubin, 2010). A study conducted by Kraft et al. (2002)
focused on the effect of clarithromycin on lung function of
M. pneumoniae infected and uninfected asthmatic patients. They
determined clarithromycin treatment caused improvement in
forced expiratory volume and reduced airway expression of IL-
5, but only in M. pneumoniae positive patients. These findings
suggest, in cases of M. pneumoniae, macrolides may act primarily
as antibiotics as well as an anti-inflammatory agent. The optimal
dosage and duration of therapy is not clear; however, 10–14 days
is generally recommended. The use of steroids in combination
with macrolides has also been recommended in severe cases of
M. pneumoniae pneumonia.
Macrolide-resistant M. pneumoniae was first reported in Japan
in Okazaki et al. (2001) and has since been continuously reported
in increasing percentages among the population (Matsuoka et al.,
2004; Miyashita et al., 2012, 2013; Kawai et al., 2013; Hanada
et al., 2014). However, the prevalence of macrolide-resistant
M. pneumoniae varies among countries. Cao et al. (2010), China
documented a 69% prevalence of resistance as well as treatment
failure, but no cases of macrolide-resistant M. pneumoniae were
found from 1997 to 2008 in the Netherlands (Spuesens et al.,
2012). It is well-established, point mutations, leading to A-to-
G transitions in the peptidyl transferase loop domain V of the
23S rRNA gene at positions 2063 and 2064, reduce the affinity
of macrolide for the ribosome (Suzuki et al., 2006; Dumke et al.,
2010a). Identification of these resistant strains currently relies
on restriction fragment length polymorphism or gene sequence
analysis. The creation of a laboratory technique, such as qRT-
PCR to rapidly detect macrolide resistant strains may be useful
for surveillance and outbreak situation.
Of the major bacterial respiratory pathogens including
Streptococcus pneumoniae and Haemophilus influenzae,
M. pneumoniae is the only one without an available vaccine
(Nir-Paz et al., 2012). During the 1960 and 1970s a number
of studies were carried out testing immunogenicity and the
protective efficacy of several different vaccines. A recent meta-
analysis by Linchevski et al. (2009), has shown the overall
pneumonia prevention efficacy of those studies was 41% (54% for
M. pneumoniae specific pneumonia), when diagnosis was based
on culture or serology. No serious adverse effects were reported
and only mild local reactions were suffered.
Schurwanz et al. (2009), P1 and P30 adhesions showed strong
reactivity with human and animal sera, proving as promising
candidates for further vaccine formulation and optimization.
However, in 2011 study reported vaccination with only an
avirulent P30 mutant resulted in disease exacerbation in mice
(Szczepanek et al., 2012). Most recently though the subcutaneous
administration of a P1–P30 chimeric recombinant protein,
followed by two intranasal booster administrations induced high,
consistent, and long lasting IgA levels in guinea pigs (Hausner
et al., 2013). The CARDS toxin could also serve as an effective
vaccine candidate (Kannan et al., 2011).
Mycoplasma pneumoniae is increasingly the cause of upper
and lower respiratory tract infections for adults and children.
It is associated with prolonged carriage and lacks natural
protective immunity following primary infections. Continued
development of a vaccine for high-risk individuals such as school
children, military recruits, and elderly people in nursing homes
or long term hospital care, may help to reduce morbidity from
pneumonia and secondary complications. A vaccine may also
slow the development of other macrolide resistant strains and
reduce the impact of macrolide-resistant strains in communities
and epidemics.
CONCLUSION
Mycoplasma pneumoniae is a commonly found pathogen within
adults around the world. It is a common cause of pneumonia
but can also initiate other extrapulmonary manifestations. The
simplicity of the genome and the small size of mycoplasmas
have led many to conclude these organisms are uncomplicated.
In reality, much regarding the microbiology and pathogenesis
of this organism remains unknown. A variety of respiratory
diseases portray similar clinical symptoms. Recent and continued
advances in multiplex PCR and qRT-PCR may prove useful in
distinguishing the pathogen causing disease. In many situations,
the mild symptoms of M. pneumoniae pneumonia may be
ignored by the patient and remain undiagnosed.
Much energy has been devoted to the CARDS toxin.
Information regarding its structure and involvement in
pathogenesis may prove useful to the continued development
of more effective options for both diagnostics and therapies.
Currently, there is limited availability of rapid and accurate
testing methods for M. pneumoniae. Further development of
rapid tests specifically to distinguish macrolide-resistant strains
may also be useful within Asia. Physicians and patients around
the world must continue to monitor macrolide-resistance strains,
preventing dissemination and increased incidence. However,
the development of an effective vaccine could prove useful at
reducing the burden among the elderly and within the workforce
around the world.
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